Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | September 01, 2026 | September 01, 2026 |
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director | June 24, 2026 | June 25, 2026 |
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Director | April 15, 2026 | April 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date September 01, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,784 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Sale · Disposed 5,000 · Balance 10,784 |
Foghorn Therapeutics Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2036-06-23 | Direct | 28,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.
IONIS PHARMACEUTICALS INC
Report date April 15, 2026 · Filed April 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,344 |
Ending reported balance
After 2026-04-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-15 · Sale · Disposed 4,466 · Balance 51,878 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.77 to $76.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Row 2 · 2026-04-15 · Sale · Disposed 534 · Balance 51,344 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.85 to $77.115 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.77 to $76.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.85 to $77.115 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AKCEA THERAPEUTICS, INC.
Report date October 12, 2020 · Filed October 13, 2020
Section 16 reporting ended · disclosed 2020-10-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.14 · Expires 2030-04-12 | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-12 · Disposition to issuer · Disposed 26,400 · Balance 0 F1: This option, which provided for vesting of the shares on April 13, 2021, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, which provided for vesting of the shares on April 13, 2021, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2017 Filed Jul 3, 2017 21:38 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 90 | $40.66 | $3,659.00 |
DisclosureSEC source: 0000874015-17-000048 · edgar.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,741 F1 · kind: Reporting 90 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 90 shares may not be sold until January 2, 2018. F1 · shares: Reporting 90 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 90 shares may not be sold until January 2, 2018. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:56 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001061983-17-000033 · edgardoc.xml · derivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 00:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,625 | $0.00 Strike: $14.69 | $0.00 |
DisclosureSEC source: 0000874015-17-000023 · edgar.xml · derivative · entry 3 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,785 Underlying: Common Stock · 4,625 shares Expires 2020-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 00:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 4,625 | $49.26 | $227,827.50 |
DisclosureSEC source: 0000874015-17-000023 · edgar.xml · nonDerivative · entry 2 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,651 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.20 to $49.32, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 00:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 4,625 | $14.69 | $67,941.25 |
DisclosureSEC source: 0000874015-17-000023 · edgar.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,076 | $46.29 | $96,096.59 |
DisclosureSEC source: 0000874015-17-000012 · edgar.xml · nonDerivative · entry 8 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,651 F8 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. F8 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,696 | $46.29 | $124,796.49 |
DisclosureSEC source: 0000874015-17-000012 · edgar.xml · nonDerivative · entry 6 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,245 F6 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. F6 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,509 | $46.29 | $69,850.86 |
DisclosureSEC source: 0000874015-17-000012 · edgar.xml · nonDerivative · entry 4 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,422 F4 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. F4 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 965 | $46.29 | $44,670.04 |
DisclosureSEC source: 0000874015-17-000012 · edgar.xml · nonDerivative · entry 2 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,494 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 30, 2013. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 30, 2013. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 4,482 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000012 · edgar.xml · derivative · entry 13 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,443 Underlying: Common Stock · 4,482 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F8 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 5,519 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000012 · edgar.xml · derivative · entry 12 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,038 Underlying: Common Stock · 5,519 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F6 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 3,437 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000012 · edgar.xml · derivative · entry 11 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,437 Underlying: Common Stock · 3,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 2,595 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000012 · edgar.xml · derivative · entry 10 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,595 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 30, 2013. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 19,606 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000012 · edgar.xml · derivative · entry 9 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,606 Underlying: Common Stock · 19,606 shares Expires not disclosed F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F10 · derivative.exercise_date: Grant 1/15/2017 to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2021. The RSU is vested as to 0 shares on January 15, 2017. F10 · derivative.expiration_date: Grant 1/15/2017 to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2021. The RSU is vested as to 0 shares on January 15, 2017. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 4,482 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000012 · edgar.xml · nonDerivative · entry 7 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2016. F7 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2016. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 5,519 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000012 · edgar.xml · nonDerivative · entry 5 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2015. F5 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2015. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 3,437 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000012 · edgar.xml · nonDerivative · entry 3 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2014. F3 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2014. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,595 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000012 · edgar.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 30, 2013. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 30, 2013. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 117,638 | $0.00 Strike: $47.34 | $0.00 |
DisclosureSEC source: 0000874015-17-000002 · edgar.xml · derivative · entry 2 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,638 Underlying: Common Stock · 117,638 shares Expires 2024-01-02 F2 · derivative.exercise_date: Grant of 1/3/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 29,410 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,032 | $4.96 Strike: $12.40 | $19,999.93 |
DisclosureSEC source: 0001061983-17-000008 · edgardoc.xml · derivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032 Underlying: Common Stock · 4,032 shares Expires 2027-01-03 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of 50% of an annual retainer of $40,000.00 F1 · derivative.exercise_date: This option shall vest and become exercisable as to 4,032 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 23:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 171 | $20.76 | $3,549.45 |
DisclosureSEC source: 0000874015-17-000002 · edgar.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,864 F1 · kind: Reporting 171 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 171 shares may not be sold until July 2, 2017. F1 · shares: Reporting 171 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 171 shares may not be sold until July 2, 2017. Read SEC document |
| December 15, 2016 Filed Dec 17, 2016 00:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-16-000151 · edgar.xml · derivative · entry 13 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Indirect · By grandchild Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2016 Filed Dec 17, 2016 00:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-16-000151 · edgar.xml · derivative · entry 12 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Indirect · By son-in-law Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2016 Filed Dec 17, 2016 00:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-16-000151 · edgar.xml · derivative · entry 11 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2016 Filed Dec 17, 2016 00:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-16-000151 · edgar.xml · derivative · entry 10 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2016 Filed Dec 17, 2016 00:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,000 | $50.00 | $50,000.00 |
DisclosureSEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 8 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Indirect · By grandchild Disclosed balance after: 0 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. Read SEC document |
| December 15, 2016 Filed Dec 17, 2016 00:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,000 | $7.25 | $7,250.00 |
DisclosureSEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 7 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Indirect · By grandchild Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. Read SEC document |
| December 15, 2016 Filed Dec 17, 2016 00:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,000 | $50.00 | $50,000.00 |
DisclosureSEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 6 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Indirect · By son-in-law Disclosed balance after: 0 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. Read SEC document |
| December 15, 2016 Filed Dec 17, 2016 00:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,000 | $7.25 | $7,250.00 |
DisclosureSEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 5 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Indirect · By son-in-law Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. Read SEC document |
| December 15, 2016 Filed Dec 17, 2016 00:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,000 | $50.00 | $50,000.00 |
DisclosureSEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 4 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 0 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. Read SEC document |
| December 15, 2016 Filed Dec 17, 2016 00:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,000 | $7.25 | $7,250.00 |
DisclosureSEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 3 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. Read SEC document |
| December 15, 2016 Filed Dec 17, 2016 00:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,000 | $50.00 | $50,000.00 |
DisclosureSEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 2 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 0 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. Read SEC document |
| December 15, 2016 Filed Dec 17, 2016 00:21 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,000 | $7.25 | $7,250.00 |
DisclosureSEC source: 0000874015-16-000151 · edgar.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/3/2016. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 23:58 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $14.69 | $0.00 |
DisclosureSEC source: 0000874015-16-000148 · edgar.xml · derivative · entry 5 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,410 Underlying: Common Stock · 12,500 shares Expires 2020-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Grant of 1/30/2013 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/2/2014. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 15,570 shares per year. Following this transaction, the option was exercisable as to 9,815 on 12/1/2016. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 23:58 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,500 | $43.17 | $237,435.00 |
DisclosureSEC source: 0000874015-16-000148 · edgar.xml · nonDerivative · entry 4 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,693 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.60 to $43.50, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 23:58 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 5,500 | $14.69 | $80,795.00 |
DisclosureSEC source: 0000874015-16-000148 · edgar.xml · nonDerivative · entry 3 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 23:58 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 7,000 | $41.49 | $290,430.00 |
DisclosureSEC source: 0000874015-16-000148 · edgar.xml · nonDerivative · entry 2 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,693 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $42.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 23:58 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 7,000 | $14.69 | $102,830.00 |
DisclosureSEC source: 0000874015-16-000148 · edgar.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 22:52 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,635 | $0.00 Strike: $14.69 | $0.00 |
DisclosureSEC source: 0000874015-16-000135 · edgar.xml · derivative · entry 6 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,910 Underlying: Common Stock · 3,635 shares Expires 2020-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant of 1/30/2013 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/2/2014. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 15,570 shares per year. Following this transaction, the option was exercisable as to 18,422 on 9/1/2016. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 22:52 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Options (right to buy) · Derivative | 8,865 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-16-000135 · edgar.xml · derivative · entry 5 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,865 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 22:52 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 3,635 | $30.05 | $109,231.75 |
DisclosureSEC source: 0000874015-16-000135 · edgar.xml · nonDerivative · entry 4 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,693 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 22:52 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 3,635 | $14.69 | $53,398.15 |
DisclosureSEC source: 0000874015-16-000135 · edgar.xml · nonDerivative · entry 3 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 22:52 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 8,865 | $29.82 | $264,313.52 |
DisclosureSEC source: 0000874015-16-000135 · edgar.xml · nonDerivative · entry 2 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,693 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.80 to $30.05, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 22:52 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 8,865 | $7.25 | $64,271.25 |
DisclosureSEC source: 0000874015-16-000135 · edgar.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 7/13/2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.